|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Advances and challenges in laparoscopic surgery in the management of hepatocellular carcinoma显示文摘Hepatocellular carcinoma is the fifth most common malignancy and the third most common cause of cancer-related mortality worldwide. From the wide variety of treatment options, surgical resection and liver transplantation are the only therapeutic ones. However, due to shortage of liver grafts, surgical resection is the most common therapeutic modality implemented. Owing to rapid technological development, minimally invasive approaches have been incorporated in liver surgery. Liver laparoscopic resection has been evaluated in comparison to the open technique and has been shown to be superior because of the reported decrease in surgical incision length and trauma, blood loss, operating theatre time, postsurgical pain and complications, R0 resection, length of stay, time to recovery and oral intake. It has been reported that laparoscopic excision is a safe and feasible approach with near zero mortality and oncologic outcomes similar to open resection. Nevertheless, current indications include solid tumors in the periphery < 5 cm, especially in segments Ⅱ through Ⅵ, while according to the consensus laparoscopic major hepatectomy should only be performed by surgeons with high expertise in laparoscopic and hepatobiliary surgery in tertiary centers. It is necessary for a surgeon to surpass the 60-cases learning curve observed in order to accomplish the desirable outcomes and preserve patient safety. In this review, our aim is to thoroughly describe the general principles and current status of laparoscopic liver resection for hepatocellular carcinoma, as well as future prospects. | Ioannis A Ziogas Georgios Tsoulfas | 2017 | World Journal of Gastrointestinal Surgery2017，9，12： | 10 |
| 2 | Evolving role of Sorafenib in the management of hepatocellular carcinoma显示文摘Hepatocellular carcinoma(HCC) is one of the most common malignant diseases worldwide and comes third in cancer-related mortality.Although there is a broad spectrum of treatment options to choose from,only a few patients are eligible candidates to receive a curative therapy according to their stage of disease,and thus palliative treatment is implemented in the majority of the patients suffering from liver cancer.Sorafenib,a multikinase inhibitor,is the only currently approved agent for systemic therapy in patients with advanced stage HCC and early stage liver disease.It has been shown to improve the overall survival,but with various side effects,while its cost is not negligible.Sorafenib has been in the market for a decade and has set the stage for personalized targeted therapy.Its role during this time has ranged from monotherapy to neoadjuvant and adjuvant treatment with surgical resection,liver transplantation and chemoembolization or even in combination with other chemotherapeutic agents.In this review our aim is to highlight in depth the current position of Sorafenib in the armamentarium against HCC and how that has evolved over time in its use either as a single agent or in combination with other therapies. | Ioannis A Ziogas Georgios Tsoulfas | 2017 | World Journal of Clinical Oncology2017，8，3： | 4 |
| 3 | Mortality risk after preoperative versus postoperative chemotherapy and radiotherapy in lymph node-positive rectal cancer显示文摘 | Seery T E Ziogas A Lin B S | 2013 | Journal of Gastrointestinal Surgery2013，17，2： | 1 |
| 4 | Associations of a polymorphism in the ornithine decarboxylase gene with colorectal cancer survival显示文摘 | Zell J A Ziogas A Ignatenko N | 2009 | Clin Cancer Res2009，15，19： | 1 |
| 5 | Prognostic factors for survival in ex?tensive stage small cell lung cancer (ED-SCLC) : the importance of smoking history, socioeconomic and marital statuses, and eth?nicity显示文摘 | Ou SH Ziogas A Zell lA | 2009 | J Thorac Oncol2009，4，1： | 1 |
| 6 | Germline polymorphisms in SIPA1 are associated with metastasis and other indicators of poor prognosis in breast cancer显示文摘 | Crawford NP Ziogas A Peel DJ | 2006 | Breast Cancer Res2006，8，2： | 1 |
| 7 | Annlysis of a static power converter under unbance: a novel approach 显示文摘 | ENJTI P A ZIOGAS P D | 1990 | IEEE Trans Ind Electr1990，37，1： | 1 |
| 8 | AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001显示文摘 | Marinov M Ziogas A Pardo OE | 2009 | Clin Cancer Res2009，15，4： | 1 |
| 9 | Diet and predictors of dietary intakes in women with family history of breast and/or ovarian cancer 显示文摘 | McEligot AJ Mouttapa M Ziogas A | 2009 | Cancer Epidemiol2009，33，6： | 1 |
| 10 | Prognostic factors for survival in extensivestage small cell lung cancer(ED-SCLC):the importance of smoking history,socioeconomic and marital,and ethnicity显示文摘 | Ou SH Ziogas A Zell JA | 2009 | Thorac Oncol2009，4，1： | 1 |
| 11 | Role of surgical resection among chemotherapy-treated patients with colorectal cancer stage IV disease: A survival analysis 显示文摘 | Lin BS Ziogas A seery TE | 2011 | J Clin Oncol2011，，： | 1 |
| 12 | Prognostic factors for survival in extensive stage small cell lung cancer (ED-SCLC):the importance of smoking history,socioeconomic and marital statuses,and ethnicity显示文摘 | Ou SH Ziogas A Zell JA | 2009 | J Thorac Oncol2009，4，1： | 1 |
| 13 | Prognostic Factors for Survival of Stage I nonsmall cell lung cancer patients显示文摘 | OU S H ZELL J A ZIOGAS A ef al | 2007 | Cancer2007，110，7： | 1 |
| 14 | The reporting quality of studies investigating the diagnostic accuracy of anti-CCP antibody in rheumatoid arthritis and its impact on diagnostic esti- mates显示文摘 | Zintzaras E Papathanasiou A Ziogas DC | 2012 | BMC Musculoskelet Disord2012，13，1： | 1 |
| 15 | Micro reactorhydrogen production from ethylene glycol reforming using Rh catalysts supported on CeO2 and La2 O3 promoted Al2 O3 显示文摘 | IZQUIERDO U WICHERT M KOLB G BARRIO V L ZAPF R ZIOGAS A NEUBERG S ARIAS P L CAMBRA J F | 2014 | Int J HydrogenEnergy2014，39，10： | 1 |
| 16 | An active power factor correction technique for three-phase diode rectifiers显示文摘 | Prasad A R Ziogas P D Manias S | 1991 | IEEE Transactions on Power Electronics1991，6，1： | 1 |
| 17 | Epidemiology of brochioloalveolar carcinoma: improvement in survival after release of the 1999 WHO classification of lung tumors 显示文摘 | Zell JA Ou SH Ziogas A | 2005 | J Clin Oncol2005，23，11： | 1 |
| 18 | Primary signet-ring carcinoma (SRC) of the lung: a population-based epidemiologic study of 262 cases with comparison to adenocarcinoma of the lung显示文摘 | Ou SH Ziogas A ZellJA | 2010 | J Thorac Oncol2010，5，4： | 1 |
| 19 | Associations of a polymorphism in the ornithine decarboxylase gene with colorectal cancer survival显示文摘 | Zell JA Ziogas A Ignatenko N | | 0，，19： | 1 |
| 20 | Breast cancer risk and methylenetetrahydrofolate reductase polymorphism显示文摘 | SEMENZA J C DELFINO R J ZIOGAS A | 2003 | Breast Cancer Res Treat2003，77，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员